Preexisting Antiviral Immunity and Allogeneic T-Cell Transfer: Redefining the Therapeutic Landscape of Progressive Multifocal Leukoencephalopathy
Posted inInfectious Diseases Neurology news

Preexisting Antiviral Immunity and Allogeneic T-Cell Transfer: Redefining the Therapeutic Landscape of Progressive Multifocal Leukoencephalopathy

Recent studies highlight the critical role of virus-specific T-cells in treating progressive multifocal leukoencephalopathy. Pre-existing T-cells predict superior responses to checkpoint inhibitors, while allogeneic T-cell transfer offers a promising rescue therapy for patients with profound immunodeficiency, significantly reducing viral loads and improving clinical outcomes.
Ultra-Early ILR Implantation Post-Cryptogenic Stroke Dramatically Improves Silent AF Detection: Insights from the CRIPTOFAST Trial
Posted inCardiology Neurology news

Ultra-Early ILR Implantation Post-Cryptogenic Stroke Dramatically Improves Silent AF Detection: Insights from the CRIPTOFAST Trial

The CRIPTOFAST trial demonstrates that ultra-early implantation of internal loop recorders significantly increases silent atrial fibrillation detection in cryptogenic stroke patients, particularly those with subtle left atrial anomalies, offering a targeted approach to secondary stroke prevention.
Low-Dose Rivaroxaban Fails to Halt Cognitive Decline in Low-Risk Atrial Fibrillation: Results from the BRAIN-AF Trial
Posted inCardiology Neurology news

Low-Dose Rivaroxaban Fails to Halt Cognitive Decline in Low-Risk Atrial Fibrillation: Results from the BRAIN-AF Trial

The multicenter BRAIN-AF trial found that rivaroxaban did not prevent cognitive decline or stroke in patients with atrial fibrillation and low CHA2DS2-VASc scores. Despite significant cognitive deterioration observed across both groups, the trial was halted early for futility, highlighting the complexity of AF-related neurocognitive impairment.
Genetic Risk Profile Predicts Stroke Prevention Benefit From Continuous Atrial Fibrillation Screening: A Secondary Analysis of the LOOP Study
Posted inCardiology Neurology news

Genetic Risk Profile Predicts Stroke Prevention Benefit From Continuous Atrial Fibrillation Screening: A Secondary Analysis of the LOOP Study

A secondary analysis of the LOOP study demonstrates that continuous ECG screening with implantable loop recorders significantly reduces stroke and systemic embolism in individuals with high genetic risk for atrial fibrillation, while potentially increasing bleeding risk in lower-risk cohorts.
Atorvastatin Attenuates Aneurysmal Wall Inflammation in Vertebrobasilar Dissecting Aneurysms: Insights from a Randomized Controlled Trial
Posted inNeurology news Radiology

Atorvastatin Attenuates Aneurysmal Wall Inflammation in Vertebrobasilar Dissecting Aneurysms: Insights from a Randomized Controlled Trial

A randomized controlled trial demonstrates that 6-month atorvastatin treatment significantly reduces aneurysm wall enhancement and systemic inflammatory markers in patients with unruptured vertebrobasilar dissecting aneurysms, potentially offering a non-invasive stabilizing therapy for these high-risk lesions.
Predicting Stroke Recurrence: MRI Markers Outperform Location in Risk-Stratifying Patients with ICH and Atrial Fibrillation
Posted inCardiology Neurology news

Predicting Stroke Recurrence: MRI Markers Outperform Location in Risk-Stratifying Patients with ICH and Atrial Fibrillation

A secondary analysis of the PRESTIGE-AF trial reveals that specific MRI markers, including cortical superficial siderosis and macrohemorrhages, are more potent predictors of recurrent intracerebral hemorrhage than hematoma location alone, offering a path toward individualized anticoagulation strategies.
Edaravone Dexborneol Improves Functional Recovery Following Endovascular Thrombectomy: Primary Results from the TASTE-2 Trial
Posted inNeurology news

Edaravone Dexborneol Improves Functional Recovery Following Endovascular Thrombectomy: Primary Results from the TASTE-2 Trial

The multicenter TASTE-2 trial reveals that edaravone dexborneol significantly increases the likelihood of functional independence at 90 days for acute ischaemic stroke patients undergoing thrombectomy, particularly those presenting with a clinical-radiological mismatch, while maintaining a safety profile comparable to placebo.